SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Tesaro, Inc. (TSRO)

NEW YORK, Jan. 16, 2018

The investigation concerns whether Tesaro and certain of its officers and/or directors have violated Sections federal securities laws.

On January 12, 2018, Tesaro announced that it had updated the U.S. labeling for Varubi (rolapitant), indicated for the prevention of delayed nausea and vomiting associated with chemotherapy, after receiving reports of "[a]naphylaxis, anaphylactic shock and other serious hypersensitivity reactions . . . in the postmarketing setting, some requiring hospitalization."  The Company further stated that it "has issued a Dear Healthcare Professional (DHCP) letter."  Following this news, Tesaro stock dropped sharply during intraday trading on January 16, 2018.

If you are aware of any facts relating to this investigation, or purchased shares of Tesaro, you can assist this investigation by visiting the firm's site: www.bgandg.com/tsro. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com